News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

David M. O'Malley, MD, The Ohio State University

Articles by David M. O'Malley, MD, The Ohio State University

Endometrial Cancer: Chemo-Free Regimens on the Horizon

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Emerging Agents: Treatment of Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Sequencing for Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Recurrent Endometrial Cancer: Safety of Combination Therapy

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Combination Therapy for Recurrent Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Emerging ICI Therapy for Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Immune Checkpoint Inhibitors in Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

GOG-258 and PORTEC-3 Studies in Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

GOG-249 Study in Early-Stage Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

GOG 0209 Study in Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Role of Biomarker Testing in Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Risk Classification of Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Overview of Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Trending on OncLive

Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC

Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer

Dr Cerchione on the FDA Approval of Subcutaneous Isatuximab in Myeloma

CAR T-Cell Engineering Produces Early Efficacy Signals in Glioblastoma

Adjuvant Penpulimab Improves DFS in Very High-Risk Clear Cell RCC